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BACKGROUND: Only 25% of IVF transfer cycles lead to a clinical pregnancy, calling for continued technical
progress but also more in depth analysis of patients’ individual characteristics. The interleukin-1 (IL-1) system and
matrix metalloproteinases (MMPs) are strongly implicated in embryo implantation. The genes coding for IL-1Ra
(gene symbol IL-1RN), IL-1b, MMP2 and MMP9 bear functional polymorphisms. We analysed the maternal
genetic profile at these polymorphic sites in IVF patients, to determine possible correlations with IVF outcome.
METHODS: One hundred and sixty women undergoing an IVF cycle were enrolled and a buccal smear was obtained.
The presence of IL-1RN variable number of tandem repeats and IL-1B1 3953, MMP2-1306 and MMP9-1562 single
nucleotide substitutions were determined. Patients were divided into pregnancy failures (119), biochemical pregnan-
cies (8) and clinical pregnancies (33). RESULTS: There was a 40% decrease in IL-1RN*2 allele frequency (P5 0.024)
and a 45% decrease in IL-1RN*2 carrier status in the clinical pregnancy group as compared to the pregnancy failure
group (P5 0.017). This decrease was still statistically significant after a multivariate logistic regression analysis. The
likelihood of a clinical pregnancy was decreased accordingly in IL-1RN*2 carriers: odds ratio5 0.349, 95% confi-
dence interval5 0.2–0.8, P5 0.017. The IL-1B, MMP2 and MMP9 polymorphisms showed no correlation with
IVF outcome. CONCLUSIONS: IL-1RN*2 allele carriage is associated with a poor prognosis of achieving a pregnancy
after IVF.
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Introduction
Epidemiological studies have shown that despite continued
improvements in assisted reproductive technologies, the clini-
cal pregnancy rate after IVF has remained at about 25% since
1993 (Van den Bergh et al., 2005; Wunder et al., 2005). Clini-
cal and fundamental research efforts are, therefore, still neces-
sary to understand reasons for this limitation and to improve
outcomes.
Achievement of pregnancy relies both on embryo quality
and the implantation capability of the maternal endometrium
(Chung et al., 2006). Therefore, in addition to technical
advances leading to the improved embryo quality, preliminary
biochemical studies have opened the way to an evaluation of
patients’ chances to become pregnant after IVF (for review,
Broekmans et al., 2006). Likewise, genotypic studies have
been conducted on several genes such as p53 (Kay et al.,
2006), HLA-G (for review Hviid, 2006) or the FSH receptor
(Jun et al., 2006), and suggest that certain genetic profiles
may be more advantageous than others in achieving a clinical
pregnancy after IVF.
Embryo implantation is composed of two processes, an
inflammation phase and an invasion phase. The interleukin-1
(IL-1) system is an important part of the innate immune
system. It consists of two agonists (IL-1a and IL-1b), one antag-
onist (IL-1Ra) and two receptors (IL-1RI and IL-1RII), of which
only IL-1RI is biologically active (for review: Sunder and
Lenton, 2000). The IL-1b/IL-1Ra ratio defines the overall
IL-1 pro-inflammatory response. Animal studies have demon-
strated that mice injected with IL-1Ra exhibited a decreased
blastocyst implantation frequency, whereas transfer of the
same blastocysts to pseudo-pregnant animals reversed this ten-
dency. The hypothesis was that IL-1 produced by the embryo,
by interacting with receptors expressed in the maternal endome-
trium, mediated implantation by inducing production of vascu-
lar endothelial growth factor and integrins along with other
mediators (for review: Sunder and Lenton, 2000).
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Matrix metalloproteinase (MMP)-2 and -9 are associated
with syncytiotrophoblast cell penetration into the maternal
endometrium and establishment of the placental barrier via
spiral arteries invasion (for review: Curry and Osteen, 2003).
Knockout mice studies showed that the absence of MMP2
resulted in offspring that were smaller at birth and had a
decreased growth rate (Itoh et al., 1997), whereas the
absence of MMP9 resulted in a decreased breeding efficiency
(Vu et al., 1998; Dubois et al., 1999, 2000).
The genes coding for IL-1Ra (gene symbol IL-1RN), IL-1B,
MMP2 and MMP9 all possess genetic polymorphisms in their
sequences: the IL-1B gene has three single nucleotide poly-
morphisms (SNPs) at positions 2511 and 231 in the promoter
region and þ3953 in the coding region; the IL-1RN gene has a
variable number (1–6) of tandem repeats (VNTR) of an 86 bp
motif in an intronic region; the MMP2 gene has a SNP at pos-
ition 21306 in the promoter region, and the MMP9 gene has a
SNP at position 21562 and a (CA)n microsatellite at position
290 in the promoter region.
Fetal carriage of IL-1RN allele 1 (IL-1RN*1) was reported
to be linked with an increased rate of spontaneous abortion in
women (Perni et al., 2004), and maternal carriage of
IL-1RN*2 was 3-fold more frequent in women with a recurrent
pregnancy loss (Unfried et al., 2001). Maternal genetic variants
at IL-1B-511C and IL-1B-31T were shown to be associated
with an increased rate of recurrent pregnancy loss (Wang
et al., 2002); the IL-1Bþ3953 polymorphism was not
examined. Finally, MMP2 and MMP9 polymorphisms have
never been evaluated in a pregnancy outcome context. We
recently showed that the MMP2 polymorphism was associated
with a higher risk of intrauterine growth retardation in
Caucasian fetuses (Gremlich et al., 2007). It has to be empha-
sized that none of the above studies were done on an IVF
population.
We, therefore, decided to investigate a possible link between
the maternal genetic profile and pregnancy outcome in an IVF
population, to determine if maternal carriage of any particular
allele could influence IVF success. Such a finding would be of
value as a prognostic indication of a woman’s likelihood of a
successful IVF outcome.
Material and Methods
Patients and treatment
The patient cohort in this prospective study was composed of women
consulting at the Reproductive Medicine Unit of the CHUV hospital
between September 2003 and September 2005. Pregnancy follow-up
was done by the Reproductive Medicine Unit.
Inclusion criteria were the following of a standard IVF protocol
without any modification and providing written informed consent to
participate in the study. Exclusion criteria were maternal use of an
immunosuppressive drug (e.g. cortisone), maternal pathology or
genetic anomaly, maternal inflammatory disease, uterine malfor-
mation, diabetes or lupus erythematosus.
Patients either followed a fresh embryo transfer protocol
(stimulated-cycle IVF), or a frozen–thawed embryo transfer protocol
(natural-cycle IVF) (embryo frozen at the two pronuclei zygote stage).
In fresh cycles, for controlled ovarian stimulation (Germond et al.,
2002), patients were desensitized with GnRH agonist (Decapeptyl;
Ferring, Zu¨rich, Switzerland) and follicular growth stimulated with
recombinant FSH (Gonal-F; Serono, Switzerland; Puregon,
Organon, Switzerland). When at least two follicles reached 17 mm
in diameter, HCG (Profasi; Serono, Switzerland) was administered.
In frozen–thawed cycles, patients monitored their own urine using a
commercially available qualitative LH test (OVU-LH; Intex,
Muttenz, Switzerland). Transfers were planned 3 days after the LH
peak. Thawing of the zygotes was planned 24–26 h earlier, in order
to allow for at least one mitotic division to occur. In cases of anovula-
tion, embryos were replaced in artificial cycles using pituitary desen-
sitization in association with estradiol (Progynova; Schering, Baar)
and progesterone (Utrogestan; Vifor, Fribourg, Switzerland) adminis-
tration (de Ziegler and Frydman, 1990). Fourteen days after the trans-
fer, a blood sample was retrieved for a pregnancy test. Pregnancy
failure was defined by a bHCG level ,2 UI/L. Biochemical preg-
nancy was defined by a bHCG level between 11 and 1000 UI/L,
followed by a decrease of the value and associated with the absence
of gestational sac at embryo transfer day 28 (ET28) assessed by ultra-
sound. Clinical pregnancy was defined by a bHCG level .1000 UI/
L, doubling every 48 h, and associated with the presence of a gesta-
tional sac at ET28 and presence of cardiac activity at ET35 assessed
by ultrasound.
The study protocol was approved by the clinical research ethical
committee of the Biology and Medicine Faculty of the University of
Lausanne.
Genetic analysis
Buccal smears were frozen at 2808C until use. Upon thawing, they
were resuspended in 240 ml NID buffer (50 mM KCl, 10 mM Tris–
HCl pH 8.3, 2.5 mM MgCl2, 1% Brij 35) and, after the addition of
10 ml proteinase K (5 mg/ml), incubated 1 h at 568C to allow
protein digestion. Proteinase K was then inactivated by a 10 min
heating at 958C, and DNA samples used for PCR analysis as described
below. Primers are listed as forward, then reverse.
IL-1RN VNTR (86-bp repeat in intron 2)
IL-1RN gene polymorphism was analysed as already described (Genc
et al., 2002). The polymorphic region was amplified by PCR: 35 cycles
(30 s at 948C, 45 s at 608C, 45 s at 728C) with primers 50-CTCAGC
AACACTCCTAT-30 and 50-TCCTGGTCTGCAGGTAA-30. The PCR
products were analysed by agarose gel electrophoresis. IL-1RN*1
allele corresponded to a 410 bp fragment (four copies of the 86-bp
repeat), IL-1RN*2 to a 240-bp fragment (two copies), IL-1RN*3 to a
325-bp fragment (three copies), IL-1R*4 to a 500-bp fragment (five
copies), IL-1RN*5 to a 585-bp fragment (six copies) and IL-1RN*6
to a 155-bp fragment (one copy).
IL-1B(Cþ3953T) polymorphism
IL-1B gene polymorphism was analysed as already described (Genc
et al., 2002). Polymorphism region was amplified by PCR: three
cycles (2 min at 948C, 2 min at 558C, 1 min at 748C) followed by
32 cycles (30 s 948C, 45 s at 558C, 45 s at 728C) with primers
50-GTTGTCATCAGACTTTGACC-30 and 50-TTCAGTTCATATG
GACCAGA-3’. PCR products were digested 2 h at 658C with
TaqI restriction enzyme and analysed by agarose gel electrophoresis.
Undigested PCR fragment was 249-bp in size (allele T, allele E2),
whereas digested fragment yielded two sub-fragments of 114 and
135 bp (allele C, allele E1).
MMP2(C-1306T) polymorphism
MMP2 gene polymorphism was analysed as already described
(Gremlich et al., 2007). Polymorphism region was amplified by
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PCR: 40 cycles (30 s at 948C, 30 s at 648C, 30 s at 728C) with primers
50-ATATTCCCCACCCAGCAGTC-30 and 50-TTGGGAACGCCTG
ACTTCAG-30. Original sequence of the forward primer was modified
to create an artificial AccI recognition sequence at the site of the
mutation (underlined nucleotide). PCR products were digested one
hour at 378C with AccI and analysed by agarose gel electrophoresis.
If there was a C to T transition, the 122 bp PCR fragment generated
two sub-fragments of 19 and 103 bp.
MMP9(C-1562T) polymorphism
MMP9 gene polymorphism was analysed as already described
(Gremlich et al., 2007). Mutation region was amplified by PCR: 30
cycles of 1 min at 948C, 1 min at 668C, 1 min at 728C with primers
50-GCCTGGCACATAGTAGGCCC-30 and 50-CTTCCTAGCCAGC
CGGCATC-30. Polymorphism analysis was done by restriction enzyme
digestion (1 h at 378C with SphI). If there was a C to T transition, the
436 bp PCR fragment generated two sub-fragments of 244 and 192 bp.
Statistical analyses
Differences in means were analysed using Fisher exact test, x2-test,
Mann–Whitney U-test or independent samples t-test, depending on
the type of variable (continue, discrete or categorical) and the hom-
ogeneity of variances between the two data sets. Differences in geno-
type/allele distribution were evaluated using Fisher exact tests.
Associations between IVF outcome and potential confounding
factors were evaluated by logistic regression analysis. Values of
P  0.05 were considered as statistically significant. All statistical
analyses were performed using the Statistical Package for the Social
Sciences (SPSS) 14.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patients
One hundred and sixty-nine women initially signed the consent
form, but nine subsequently withdrew. The 160 women
remaining were ultimately classified as pregnancy failures
(119), biochemical pregnancies (8) and clinical pregnancies
(33). The biochemical pregnancy rate was 5% and the clinical
pregnancy rate was 21%.
Patients’ characteristics are presented in Table I. Age and
body mass index (BMI) were comparable in all three groups,
except for a non-significant tendency among women experien-
cing a biochemical pregnancy to have a mean age and BMI
values higher than those in the other groups. Ethnic origin
and mean gravidity/parity were also comparable in all three
groups. The causes of infertility were in similar proportions
for all three groups, as was the mean number of transfers at
the time of the study and mean number of oocytes collected,
mature oocytes and the ratio between both. The only significant
difference was related to the type of transfer (fresh or frozen).
The proportion of fresh transfers was greater in women experi-
encing a biochemical pregnancy (87.5%) than in the other
groups (43.7 and 60.6%, respectively, for pregnancy failure
and clinical pregnancy groups; P ¼ 0.024 for biochemical
pregnancy versus pregnancy failure group). However, the bio-
chemical pregnancy group encompassed only eight cases so the
significance of this finding remains questionable. The clinical
pregnancy rate was 16% for frozen embryo transfers, compared
Table I. Patients characteristics.
Pregnancy failure N ¼ 119 Biochemical pregnancy N ¼ 8 Clinical pregnancy N ¼ 33 Total population N ¼ 160
Mother
Maternal age (years) 34+4 (25–44) 37+4 (31–42) 33+4 (26–42) 34+4 (25–44)
Maternal body mass index (kg/m2) 22.9+3.9 26.4+9.2 23.8+4.1 23.3+4.4
Ethnic origin: caucasian (%) 95 100 94 95
Gravidity (%):
0 57 63 40 53
1 23 12 20 23
2 20 25 40 24
Parity (%):
0 70 75 52 67
1 20 25 33 23
2 20 0 15 10
Infertility history
Infertility origin (%):
Paternal 51 37.5 55 51
Maternal 24 37.5 30 26
Both conjugated 18 25 12 18
Unknown 7 0 3 5
Infertility (%):
Primary 83 75 70 80
Secondary 17 25 30 20
Previous transfers (fresh and frozen) 3.4 6.3 3.6 3.6+3.1
Current IVF
Transfer type (%)
Fresh 43.7 87.5* 60.6 49.4
Frozen 56.3 12.5 39.4 50.6
Oocytes (%)
Collected 12.6+6.5 11.0+6.0 12.9+7.1 12.6+6.6
Ripe 10.4+5.7 8.9+5.6 10.7+5.7 10.4+5.7
Ripe/collected 0.83 0.80 0.85 0.83
No significant difference was observed between biochemical or clinical pregnancy groups, and pregnancy failure group by independent sample t-test, x2-test,
Mann–Whitney U-test or Fisher exact test, except *P ¼ 0.024 by Fisher exact test.
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to 25% for fresh embryo transfers and 24 and 22%, respect-
ively, for maternal and paternal infertility origin, compared
to 15% for combination of both. However, none of these differ-
ences was statistically significant.
Maternal genetic profile
All four gene polymorphisms studied were compatible with
Hardy–Weinberg equilibrium.
IL-1RN VNTR (86-bp repeat in intron 2)
In the pregnancy failure group, allelic frequencies were as
follows: 63% for the IL-1RN*1 allele, 34% for the
IL-1RN*2 allele and 3% for the combined IL-1RN*3, *4 and
*6 alleles (Table II, Fig. 1). In the biochemical pregnancy
group, no significant differences were observed compared to
the pregnancy failure group, except that the minor alleles
other than IL-1RN*1 or *2 were absent. In the clinical preg-
nancy group, however, the IL-1RN*1 allele frequency was
increased to 80% and the IL-1RN*2 allele frequency decreased
to 20% (P ¼ 0.026 compared with the pregnancy failure
group). Thus, IL-1RN*2 carriage decreased the chances of
clinical pregnancy compared with the IL-1RN*1 allele
as follows: odds ratio (OR) ¼ 0.472, 95% confidence interval
(CI) ¼ 0.2–0.9, P ¼ 0.024. Similarly, IL-1RN*1 homozygotes
were almost 2-fold increased and IL-1RN*1/IL-1RN*2
heterozygotes 2-fold decreased, compared with the pregnancy
failure group (P ¼ 0.016). This modified the chances of IVF
success of IL-1RN*1/IL-1RN*2 carriers compared to the
IL-1RN*1 homozygote genotype as follows: OR ¼ 0.275,
95% CI ¼ 0.1–0.7, P ¼ 0.006. The global pregnancy rate
was 29% for IL-1RN*1 homozygotes, versus 13% for
IL-1RN*2 carriers (OR ¼ 0.354, 95% CI ¼ 0.2–0.8,
P ¼ 0.018).
The pregnancy rate linked with IL-1RN*2 carriage was
different according to the number of previous IVF attempts.
When the number of previous attempts was 3, the rate of
IL-1RN*2 carriers was 54% (39 out of 72) in the pregnancy
failure group versus 23% (5 out of 22) in the clinical pregnancy
group, but when the number of previous attempts was .3, it
was 58% (27 out of 47) in pregnancy failure group versus
46% (5 out of 11) in clinical pregnancy group, modifying clini-
cal pregnancy likelihood in the following way: OR ¼ 0.249,
95% CI ¼ 0.1–0.7, P ¼ 0.014 and OR ¼ 0.617, 95% CI ¼
0.2–2.3, P ¼ 0.517, respectively. It is interesting to note that
in our study, the pregnancy rate of IL-1RN*2 carriers was
decreased in the same way whether following fresh or frozen
embryo transfers. Indeed, in fresh embryo transfers, the preg-
nancy rate was 15% (5 out of 34) in IL-1RN*2 carriers com-
pared with 33% (15 out of 45) in non-carriers, whereas in
frozen embryo transfers it was 11% (5 out of 46) compared
with 23% (8 out of 35) in non-carriers, a difference which
was not statistically significant. The choice of one or the
other transfer type, therefore, did not seem to matter for
IL-1RN*2 carriers.
IL-1B(Cþ3953T) polymorphism
For the pregnancy failure group, allele frequencies were 79%
for allele 1 and 21% for allele 2, not much different from the
81 and 19% measured in the biochemical pregnancy group
and 80 and 20% measured in the clinical pregnancy group
Table II. Genotype and allele distribution of interleukin-1 (IL-1) receptor antagonist (IL-1RN), IL-1B, matrix metalloproteinase (MMP)2 and MMP9
polymorphisms in pregnancy failure, biochemical pregnancy and clinical pregnancy groups.
Pregnancy
failure N (%)
Biochemical
pregnancy N (%)
Odds ratio 95% CI P Clinical
pregnancy N (%)
Odds ratio 95% CI P
IL-1RN Genotype *1/*1 47 (39) 4 (50) 1.000 23 (70) 1.000
*1/*2 52 (44) 3 (38) 0.678 0.1–3.2 NS 7 (21) 0.275 0.1–0.7 0.006
*2/*2 14 (12) 1 (12) 0.839 0.1–8.1 NS 3 (9) 0.438 0.1–1.7 NS
Other 6 (5) 0 (0) NA NA NA 0 (0) NA NA
*22 53 (44) 4 (50) 1.000 23 (70) 1.000
*2þ 66 (56) 4 (50) 0.803 0.2–3.4 NS 10 (30) 0.349 0.2–0.8
Allele *1 151 (63) 11 (69) 1.000 53 (80) 1.000
*2 81 (34) 5 (31) 0.864 0.3–2.6 NS 13 (20) 0.472 0.2–0.9 0.024
Other 6 (3) 0 (0) NA NA NA 0 (0) NA NA NA
IL-1B Genotype 11 78 (65) 5 (63) 1.000 20 (61) 1.000
12 33 (28) 3 (37) 1.418 0.3–6.3 NS 13 (39) 1.536 0.7–3.4 NS
22 8 (7) 0 (0) NA NA NA 0 (0) NA NA NA
Allele 1 189 (79) 13 (81) 1.000 53 (80) 1.000
2 49 (21) 3 (19) 0.890 0.2–3.2 NS 13 (20) 0.946 0.5–1.9 NS
MMP2 Genotype CC 90 (76) 5 (63) 1.000 25 (76) 1.000
CT 26 (22) 3 (37) 2.077 0.5–9.3 NS 7 (21) 0.969 0.4–2.5 NS
TT 3 (2) 0 (0) NA NA NA 1 (3) 1.200 0.1–12.0 NS
Allele C 206 (87) 13 (81) 1.000 57 (86) 1.000
T 32 (13) 3 (19) 1.486 0.4–5.5 NS 9 (14) 1.016 0.5–2.3 NS
MMP9 Genotype CC 83 (70) 5 (63) 1.000 23 (70) 1.000
CT 30 (26) 3 (37) 1.660 0.4–7.4 NS 8 (24) 0.962 0.4–2.4 NS
TT 5 (4) 0 (0) NA NA NA 2 (6) 1.443 0.3–7.9 NS
Allele C 196 (83) 13 (81) 1.000 54 (82) 1.000
T 40 (17) 3 (19) 1.131 0.3–4.2 NS 12 (18) 1.089 0.5–2.2 NS
NA, not applicable; NS, not significant; CI, confidence interval.
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(Table II). Genotype frequencies were also unchanged:
65:28:7% for genotype 1,1, 1,2 and 2,2, respectively, in the
pregnancy failure group, compared with 63:37:0% in the bio-
chemical group, and 61:39:0% in the clinical pregnancy
group. The combination of both IL-1RN VNTR and
IL-1Bþ3953 SNP did not show a further at risk group.
MMP2(C-1306T) polymorphism
For the pregnancy failure group, the allele frequency was 87%
for allele C and 13% for allele T. This was comparable to the 81
and 19% frequencies in the biochemical pregnancy group, and
the 86 and 14% frequencies in the clinical pregnancy group
(Table II). Genotype distribution was 76% CC, 22% CT and
2% TT for pregnancy failure group, 63% CC, 37% CT and
0% TT for biochemical pregnancy group and 76% CC, 21%
CT and 3%TT for clinical pregnancy group, not significantly
different in one group compared to the others.
MMP9(C-1562T) polymorphism
In the pregnancy failure group, the allele frequency was 83%
for allele C and 17% for allele T, similar to that observed in
the clinical pregnancy (82 and 18%) and biochemical preg-
nancy (81 and 19%) groups (Table II). Genotype frequencies
were also similar in all three groups: 70, 26 and 4%, respect-
ively, for CC, CT and TT genotypes in pregnancy failure
group, 63, 37 and 0% in biochemical pregnancy group and
70, 24 and 6% in clinical pregnancy group.
Logistic regression analysis
A general model comprising all the factors potentially influen-
cing a pregnancy (personal and IVF-related maternal character-
istics) plus our present results was created using the logistic
regression model analysis, to evaluate each parameter’s influ-
ence on the final IVF outcome (Table III). Only maternal
age, transfer type (fresh or frozen) and IL-1RN polymorphism
(especially the presence of one or two IL-1RN*2 allele), were
associated with IVF outcome.
Discussion
Despite ongoing efforts to increase IVF efficiency, the clini-
cal pregnancy rate still remains at 25% after each transfer
cycle (Van den Bergh et al., 2005). Therefore, a more precise
identification of patients’ individual biochemical/genetic
profiles may aid in the evaluation of each woman’s
intrinsic capacity to become pregnant, even prior to any
IVF attempt.
In this study, the maternal genetic profile at four gene poly-
morphisms associated with inflammation and/or invasion were
evaluated in a cohort of IVF patients and IL-1RN VNTR was
shown to be associated with IVF outcome.
The genotype distributions of all four polymorphisms were
similar to previous reports. Indeed, for the MMP2 and
MMP9 polymorphisms, allele T frequencies were 13 and
17%, respectively, in accordance with the 12 and 16% frequen-
cies recorded in our previous study on intrauterine growth
restriction (IUGR) (Gremlich et al., 2007). For the IL-1B and
IL-1RN polymorphisms, allele 2 frequencies were 20 and
31%, respectively, comparable to the 21–25 and the 22–
29% frequencies recorded in a previous meta-analysis report
(Camargo et al., 2006).
In this study, we found that the IL-1RN VNTR, but not
IL-1Bþ3953, polymorphism, was associated with IVF
outcome. Indeed, the clinical pregnancy rate was more than
doubled in the absence of IL-1RN*2 allele, compared with
the rate in the presence of one or two IL-1RN*2 alleles. The
IL-1RN*2 allele frequency was essentially unchanged when
the number of previous IVF attempts was .3, which probably
means that beyond three attempts, other factors probably con-
tribute to outcome. This result is consistent with a previous
study where Unfried et al. (2001) had shown that there was a
3-fold increase in IL-1RN*2 allele frequency in women with
recurrent pregnancy loss (three or more consecutive pregnancy
losses). We also found that the presence of the IL-1RN*2 allele
was associated with an absence of the IL-1Bþ3953 allele 2
(P ¼ 0.008). Santtila et al. had previously observed similar
findings utilizing DNA from peripheral blood mononuclear
cells in a non-pregnant population. Moreover, they had
shown that it was the presence or absence of the IL-1RN*2
allele, more than the presence or absence of the IL-1B þ
3953 allele 2, that was responsible for the rate of in vitro
IL-1b production, and that the effect of the IL-1RN*2 allele
was to increase IL-1b production (Santtila et al., 1998). The
IL-1RN*2 allele has also been associated with moderately
higher circulating levels of IL-1Ra protein (Hurme and
Santtila, 1998), and higher IL-1b production (Santtila et al.,
Figure 1: Interleukin-1 (IL-1) receptor antagonist IL-1RN*2 allele and genotype frequencies are decreased in the clinical pregnancy group, com-
pared to the pregnancy failure group. The IL-1RN variable number of tandem repeats genotype was assessed in a cohort of 160 IVF patients
classified as: pregnancy failures (119), biochemical pregnancies (8) and clinical pregnancies (33). Results are presented as mean+SEM
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1998; Witkin et al., 2003). The net effect of IL-1RN*2 allele
carriage is a higher IL-1b/IL-1Ra ratio and an elevated
pro-inflammatory response. Our genetic study also corrobo-
rates a previous biochemical study where Spandorfer et al.
found that a relative antagonism of the IL-1 system, i.e.
a low level of IL-1b associated with a high level of IL-1Ra
in maternal serum, was associated with a higher clinical
pregnancy rate in an IVF population (Spandorfer et al., 2003).
The IL-1RN VNTR has also been studied in the fetal
genome. Perni et al. (2004) were able to show that fetal car-
riage of IL-1RN*2 was associated with higher amniotic fluid
concentrations of IL-1b and to a lesser extent IL-1Ra, and
with a decreased history of spontaneous abortions. Altogether,
IL-1RN*2 maternal carriage seems to have a negative influ-
ence on pregnancy while fetal carriage of the same allele
may have a positive one. The inflammatory episode associated
with embryo implantation is, however, subjected to a very tight
equilibrium: a too low inflammation process could result in
implantation failure, whereas too high inflammation could
signify rejection of the embryo. It is possible that the combined
fetal and maternal genetic profile at IL-1RN VNTR is import-
ant. The potentially antagonistic contribution of both maternal
and the fetal IL-1RN genotypes can be paralleled to the situ-
ation of graft acceptance. Indeed, IL-1 gene cluster polymorph-
isms, including IL-1RN VNTR and IL-1Bþ3953 SNP, are
associated with different graft-versus-host diseases, when
present in the donor or the host (for review, Cullup and
Starck, 2005).
In the present study, we found no association between
MMP2 or MMP9 SNPs and IVF outcome. Previous indirect
evidence (animal studies and in vitro studies) had highlighted
roles for MMP2 and MMP9 in embryo implantation (for
review: Curry and Osteen, 2003) and more recently, our
group had shown that fetal carriage of MMP2-1306 poly-
morphism allele T was linked to an increased risk of IUGR
(Gremlich et al., 2007). Our present negative result does not
mean, however, that maternal MMPs production is not import-
ant in embryo implantation in IVF. Fetal carriage of MMP
polymorphisms was not evaluated and could be more important
than maternal profile in this context. We also did not evaluate
for tissue inhibitor of metalloproteinase which would influence
the extent of MMP activity. Lastly, the actual MMP protein
concentration at the site of implantation and at the time of
implantation was not measured.
In conclusion, this study confirms a predominant role of
inflammation in embryo implantation, and also adds a
genetic marker to a list of favorable/unfavorable indications
for IVF success. In the future, IL-1RN genetic profiling may
be useful to screen prospective patients prior to their initial
IVF cycle. In addition, knowledge of IL-1RN*2 carriage may
eventually result in individualized medicinal intervention
prior to any IVF attempt to modulate the maternal inflamma-
tory response, or a supplementation of the embryo culture
medium in order to minimize its influence.
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